Indivior (INDV) Stock Price, News & Analysis

Company Overview

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose. Indivior also markets other buprenorphine-based treatments and specialty medicines, including products for opioid dependence and schizophrenia-related conditions in selected markets.

Indivior was established in 2014 through the demerger of the pharmaceutical business of Reckitt Benckiser Group. The company serves patients and healthcare providers primarily in the United States, as well as in markets across Europe, Canada, Australia and other international regions. Indivior is led by Chief Executive Officer Mark Crossley and is headquartered in Richmond, Virginia.

Key Stats

• Today's Range: $35.57 to $36.28
• 50-Day Range: $34.22 to $40.99
• 52-Week Range: $22.56 to $42.81
• Volume: 2.22 million shs
• Average Volume: 2.02 million shs
• Market Capitalization: $4.25 billion
• P/E Ratio: 12.90
• Dividend Yield: N/A
• Price Target: $45.17
• Consensus Rating: Moderate Buy

Indivior Stock Analysis - MarketRank™

Indivior scored higher than 82% of companies evaluated by MarketBeat, and ranked 121st out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Indivior has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

Indivior has a consensus price target of $45.17, representing about 25.5% upside from its current price of $36.00.

Amount of Analyst Coverage

Indivior has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 4.64%

Earnings Growth

Earnings for Indivior are expected to grow by 4.64% in the coming year, from $3.66 to $3.83 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Indivior is 12.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.92.

Price to Earnings Ratio vs. Sector

The P/E ratio of Indivior is 12.90, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.39.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.54% of the float of Indivior has been sold short.

Short Interest Ratio / Days to Cover

Indivior has a short interest ratio ("days to cover") of 5.7.

Change versus previous month

Short interest in Indivior has recently decreased by 1.12%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Indivior does not currently pay a dividend.

Dividend Growth

Indivior does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.57

News Sentiment

Indivior has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Indivior this week, compared to 3 articles on an average week.

Search Interest

6 people have searched for INDV on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Indivior to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 2.2 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Indivior insiders have sold 608.28% more of their company's stock than they have bought. Specifically, they have bought $107,955.00 in company stock and sold $764,628.00 in company stock.

Percentage Held by Insiders

0.74% of the stock of Indivior is held by insiders.

Percentage Held by Institutions

60.33% of the stock of Indivior is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/30/2026
• Today: 9/25/2026
• Next Earnings (Estimated): 10/29/2026
• Record date for 11/6 Dividend: 10/30/2026
• Ex-Dividend for 11/6 Dividend: 10/30/2026
• Dividend Payable: 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:INDV
• CIK: 1625297
• Web: www.indivior.com
• Phone: 804-379-1090
• Fax: 804-379-1215
• Employees: 838
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Indivior: $45.17
• High Price Target: $53.00
• Low Price Target: $36.00
• Potential Upside/Downside: +25.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 7 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.79
• Trailing P/E Ratio: 12.90
• Forward P/E Ratio: 9.84
• P/E Growth: N/A
• Net Income: $210 million
• Net Margins: 26.65%
• Pretax Margin: 29.50%
• Return on Equity: -283.11%
• Return on Assets: 36.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.84
• Quick Ratio: 0.66

Sales & Book Value

• Annual Sales: $1.24 billion
• Price / Sales: 3.43
• Cash Flow: $2.70 per share
• Price / Cash Flow: 13.31
• Book Value: ($0.78) per share
• Price / Book: -46.15

Miscellaneous

• Outstanding Shares: 118,030,000
• Free Float: 117,159,000
• Market Cap: $4.25 billion
• Optionable: Not Optionable
• Beta: 0.82